循证医学

维基百科，自由的百科全书

zh-cn:循證醫學;zh-tw:實證醫學 (Evidence-based medicine，簡稱：EBM)，又稱zh-cn:實證醫學;zh-tw:循證醫學，為應用科学方法在醫學實踐上。According to the Centre for Evidence-Based Medicine, "Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients."^[1]

目录 1 概論 2 歷史 3 證據資格 3.1 推薦目錄 3.2 可能證據的限制 4 对循證醫學的批評 5 參見 6 參考文獻 7 外部連結

[编辑] 概論

Using techniques from 科学, 工程学 and 统计学, such as 統合分析 of scientific literature, 風險利益分析, and 随机对照试验, it aims for the ideal that 医疗卫生 professionals should make "conscientious, explicit, and judicious use of current best evidence" in their everyday practice.

Generally, there are three distinct, but interdependent, areas of EBM. The first is to treat individual patients with acute or chronic pathologies by treatments supported in the most scientifically valid medical literature. Thus medical practitioners would select treatment options for specific cases based on the best research for each patient they treat. The second area is the systemic analysis of medical literature to evaluate the best studies on specific topics. This process can be very human-centered, as in a 醫學期刊聯誼會, or highly technical using computer programs and information techniques such as 数据挖掘. Increased use of 信息技术 turns large volumes of information into practical guides. Finally, evidence-based medicine can be understood as a medical "movement", where advocates work to popularize the method and usefulness of the practice in the public, patient communities, educational institutions, and continuing education of practising professionals.

Evidence-based medicine has demoted ex cathedra statements of the "medical 專業人員" to the least valid form of evidence. All "experts" are now expected to reference their pronouncements to scientific studies.

[编辑] 歷史

Although testing medical interventions for efficacy has existed for several hundred years, and arguably more, it was only in the 20th century that this effort evolved to impact almost all fields of health care and policy. Professor Archie Cochrane, a Scottish epidemiologist, through his book Effectiveness and Efficiency: Random Reflections on Health Services (1972) and subsequent advocacy caused increasing acceptance of the concepts behind evidence-based practice. Cochrane's work was honoured through the naming of centres of evidence-based medical research — Cochrane Centres — and an international organisation, the Cochrane协作网. The explicit methodologies used to determine "best evidence" were largely established by the McMaster University research group led by David Sackett and Gordon Guyatt. The term "evidence-based medicine" first appeared in the medical literature in 1992 in a paper by Guyatt et al. ^[2]

[编辑] 證據資格

Evidence-based medicine categorizes different types of clinical evidence and ranks them according to the strength of their freedom from the various biases that beset medical research. For example, the strongest evidence for therapeutic interventions is provided by 临床研究, 雙盲, 安慰剂-controlled trials involving a homogeneous patient population and medical condition. In contrast, patient testimonials, case reports, and even expert opinion have little value as proof because of the placebo effect, the biases inherent in observation and reporting of cases, difficulties in ascertaining who is an expert, and more.

Practising evidence-based medicine implies not only clinical expertise, but expertise in retrieving, interpreting, and applying the results of scientific studies, and in communicating the risks and benefit of different courses of action to patients.

The concept of 需要治療的人數(NNT) is increasingly part of evidence-based medicine. NNT is a numerical indicator of the effectiveness of a therapy. For example, an NNT of 4 means if 4 patients are treated, only one would respond. An NNT of 1 is the most effective and means each patient treated responds, e.g., in comparing antibiotics with placebo in the eradication of 幽門螺桿菌. An NNT of 2 or 3 indicates that a treatment is quite effective (with one patient in 2 or 3 responding to the treatment). An NNT of 20 to 40 can still be considered clinically effective^[3].

Systems to stratify evidence by quality have been developed, such as this one by the U.S. Preventive Services Task Force:

• Level I: Evidence obtained from at least one properly designed randomized controlled trial.
• Level II-1: Evidence obtained from well-designed controlled trials without 隨機分配.
• Level II-2: Evidence obtained from well-designed 同期群 or 病例-對照研究 analytic studies, preferably from more than one center or research group.
• Level II-3: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.
• Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

The UK National Health Service uses a similar system with categories labelled A, B, C, and D.

[编辑] 推薦目錄

In guidelines and other publications, recommendation for a clinical service is classified by the balance of risk versus benefit of the service and the level of evidence on which this information is based. The U.S. Preventive Service Task Force uses:

• Level A: Good scientific evidence suggests that the benefits of the clinical service substantially outweighs the potential risks. Clinicians should discuss the service with eligible patients.
• Level B: At least fair scientific evidence suggests that the benefits of the clinical service outweights the potential risks. Clinicians should discuss the service with eligible patients.
• Level C: At least fair scientific evidence suggests that there are benefits provided by the clinical service, but the balance between benefits and risks are too close for making general recommendations. Clinicians need not offer it unless there are individual considerations.
• Level D: At least fair scientific evidence suggests that the risks of the clinical service outweighs potential benefits. Clinicans should not routinely offer the service to asymptomatic patients.
• Level I: Scientific evidence is lacking, of poor quality, or conflicting, such that the risk versus benefit balance cannot be assessed. Clinicians should help patients understand the uncertainty surrounding the clinical service.

This is a distinct and conscious improvement on older fashions in recommendation and the interpretation of recommendations where it was less clear which parts of a guideline were most firmly established.

The Oxford Centre for Evidence-based Medicine uses these levels of evidence (LOE) and "grades of recommendations" according to the study designs and critical appraisal of prevention, diagnosis, prognosis, therapy, and harm studies:^[4]

• Level A: consistent Randomised Controlled Clinical Trial, Cohort Study, All or None, Clinical Decision Rule validated in different populations.

• Level B: consistent Retrospective Cohort, Exploratory Cohort, Ecological Study, Outcomes Research, Case-Control Study; or extrapolations from level A studies.

• Level C: Case-series Study or extrapolations from level B studies

• Level D: Expert opinion without explicit critical appraisal, or based on physiology, bench research or first principles

"Extrapolations" are where data is used in a situation which has potentially clinically important differences than the original study situation.

[编辑] 可能證據的限制

It is recognised that not all evidence is made accessible, that this can limit the effectiveness of any approach, and that effort to reduce various publication and retrieval biases is required.

Failure to publish negative trials is the most obvious gap, and moves to register all trials at the outset, and then to pursue their results, are underway. Changes in publication methods, particularly related to the Web, should reduce the difficulty of obtaining publication for a paper on a trial that concludes it did not prove anything new, including its starting hypothesis.

Treatment effectiveness reported from clinical studies may be higher than that achieved in later routine clinical practice due to the closer patient monitoring during trials that leads to much higher compliance rates.^[5]

[编辑] 对循證醫學的批評

Critics of EBM say lack of evidence and lack of benefit are not the same, and that the more data are pooled and aggregated, the more difficult it is to compare the patients in the studies with the patient in front of the doctor — that is, EBM applies to populations, not necessarily to individuals. In The limits of evidence-based medicine^[6], Tonelli argues that "the knowledge gained from clinical research does not directly answer the primary clinical question of what is best for the patient at hand." Tonelli suggests that proponents of evidence-based medicine discount the value of clinical experience.

Although evidence-based medicine is quickly becoming the "黃金標準" for clinical practice and treatment guidelines, there are a number of reasons why most current medical and surgical practices do not have a strong literature base supporting them.

• In some cases, such as in open-heart surgery, conducting randomized controlled trials would be unethical, although 觀察性研究 are designed to address these problems to some degree.
• Certain groups have been historically under-researched (women, racial minorities, people with many co-morbid diseases), and thus the literature is sparse in areas that do not allow for generalizability.
• The types of trials considered "gold standard" (i.e. randomized double-blind placebo-controlled trials) may be expensive, so that funding sources play a role in what gets investigated. For example, public authorities may tend to fund preventive medicine studies to improve public health as a whole, while pharmaceutical companies fund studies intended to demonstrate the efficacy and safety of particular drugs.
• The studies that are published in medical journals may not be representative of all the studies that are completed on a given topic (published and unpublished) or may be misleading due to conflicts of interest (i.e. publication bias)^[7]. Thus the array of evidence available on particular therapies may not be well-represented in the literature. Since the 2004 statement by the International Committee of Medical Journal Editors that they will refuse to publish clinical trial results if the trial was not recorded publicly at its outset, this may become less of a problem.
• The quality of studies performed varies, making it difficult to generalize about the results, although well conducted meta-analyses remove poor quality studies from influencing data.

An additional problem is that large randomized controlled trials are useful for examining discrete interventions for carefully defined medical conditions. The more complex the patient population, the conditions, and the intervention, however, the more difficult it is to separate the treatment effect from random variation. Because of this, a number of studies obtain non-significant results, either because there is insufficient power to show a difference, or because the groups are not well-enough "controlled".

A particular difficulty, which in essence is related to many of the problems above, is that evidence-based guidelines do not remove the problem of induction. Even if several top-quality studies are available, questions always remain about how far, and to which populations, their results are "generalizable". Furthermore, skepticism about results may always be extended to areas not explicitly covered: for example a drug may influence a "intermediate endpoint" such as as test result (blood pressure, glucose, or cholesterol levels), or even a clinical endpoint such as number of heart attacks or tumor size, without having the power to show that it decreases overall mortality in a population. In such cases, skeptics who demand that an expensive treatment not be used until it can be shown to save lives may argue that crucial evidence is lacking.

In managed healthcare systems, evidence-based guidelines have been used as a basis for denying insurance coverage for some treatments which are held by the physicians involved to be effective, but of which randomized controlled trials have not yet been published. In some cases, these denials were based upon questions of induction and efficacy as discussed above. For example, if an older generic statin drug has been shown to reduce mortality, is this enough evidence for use of a much more expensive newer statin drug which lowers cholesterol more effectively, but for which mortality reductions have not had time enough to be shown? If a new costly therapy causes cancer to go into remission, is it justified as an expense before it is shown to save lives?

Evidence-based medicine has also been criticized for using a very specific, 计量经济学 derived form of evidence.

[编辑] 參見

• 药物不良反应
• Adverse effect (medicine)
• Clinical trials with surprising outcomes
• Consensus (medical)
• 流行病学
• 臨床診療指引（Clinical Practice Guideline，簡稱CPG）
• 医学史
• Medical algorithm
• 医学研究(Medical research)
• Nocebo
• 安慰剂(Placebo(origins of technical term))
• 系统综述(systematic review)
• 循證管理(Evidence-based management)

[编辑] 參考文獻

1. ↑ Glossary of terms in Evidence-Based Medicine Centre for Evidence-Based Medicine - 於2006-06-29zh-tw:造;zh-cn:采訪。
2. ↑ Guyatt G, Cairns J, Churchill D, et al. [‘Evidence-Based Medicine Working Group’] "Evidence-based medicine. A new approach to teaching the practice of medicine." JAMA 1992;268:2420-5. PMID 1404801
3. ↑ McQuay·Henry J.； Moore, R. Andrew （1997-05-01） - Numbers Needed to Treat Bandolier - 於2006-06-27zh-tw:造;zh-cn:采訪。
4. ↑ Oxford Centre for Evidence-based Medicine Levels of Evidence and Grades of Recommendation
5. ↑ "Patient Compliance with statins" Bandolier Review 2004
6. ↑ Tonelli·MR （2001） - The limits of evidence-based medicine NCBI PubMed - 於2006-06-27zh-tw:造;zh-cn:采訪。
7. ↑ Friedman·LS； Richter, ED （2004） - Relationship between conflicts of interest and research results NCBI PubMed - 於2006-06-27zh-tw:造;zh-cn:采訪。

[编辑] 外部連結

• ACC.org - 'What Is Evidence-Based Medicine?' American College of Cardiology
• AHRQ.gov - 'U.S. Preventive Services Task Force (USPSTF)', Agency for Health Care Research and Quality
• BEEMCourse.com - 'The Best Evidence In Emergency Medicine (BEEM) Team' Group based out of McMaster University (Hamilton, Ontario, Canada) that actively reviews the best emerging evidence based research in emergency medicine.
• BMJ.com - 'Evidence based medicine: what it is and what it isn't: It's about integrating individual clinical expertise and the best external evidence', (editorial) British Medical Journal, vol 312, p 71-72 (January 13, 1996)

• BMJ.com - 'Evidence based medicine: Socratic dissent', (Education and debate) British Medical Journal, vol 310, p 1126-1127 (April 29, 1995)

• CEBM.net - Oxford Centre for Evidence-Based Medicine (UK)
• CMAJ.ca - 'Evidence-based medicine: a commentary on common criticisms', Dr. Sharon E. Straus, Dr. Finlay A. McAlister, Canadian Medical Association Journal, Vol 163, No 7, pp 837 - 841 (October 3, 2000)
• Cochrane.org - 'The Cochrane Collaboration: The reliable source for evidence in healthcare' (systematic reviews of the effects of health care interventions), Cochrane Library
• EBOnCall.org - 'Evidence compendia' (evidence-based summaries of 38 on-call medical conditions), Evidence-Based On-Call (EBOC)
• GPNoteBook.co.uk - 'Evidence-based medicine (EBM)', General Practice Notebook
• HERTS.ac.uk - Evidence-Based Medicine', University of Hertfordshire
• JournalReview.org - 'An unbiased forum for review of the medical literature', An On-Line journal club
• JR2.ox.ac.uk - 'Bandolier: Evidence-based thinking about health care', Bandolier (journal)
• MJA.com.au - 'Evidence-based medicine: useful tools for decision making', Jonathan C. Craig, Les M. Irwig, Martin R. Stockler, Medical Journal of Australia, vol 174, p 248-253 (2001)
• SHEF.ac.uk - 'Netting the Evidence: A ScHARR Introduction to Evidence Based Practice on the Internet' (resource directory), University of Sheffield
• TRIPDatabase.com - 'TRIP Database - EBM search engine' (resource directory), TRIP Knowledge Service